Mayako Yamazaki - Concepedia

Author

Mayako Yamazaki

Astellas Pharma (Japan)ORCID

Also Known As

M Yamazaki, M. Yamazaki, Mayako Yamazaki

Publications

547

Citations

H-Index

Concepts

All Affiliations

Astellas Pharma (Japan)Eisai (Japan)Mochida Pharmaceutical (Japan)Fujisawa City Hospital

About

Mayako Yamazaki is an author at Astellas Pharma (Japan) specializing in medicine, neuroscience, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	11	308
2	Social Sciences	5	5	129
3	Health Sciences	1	1	32
4	Natural Sciences	1	1	27
5	Allergy	1	1	16

Mayako Yamazaki

Publications

501

Citations

H-Index

Page 1

	Year	Citations
A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease Katsuya Harada, Kazuhiro Nakato, Junko Yarimizu, European Journal of Pharmacology Alzheimer's DiseaseMedicineCognitive DysfunctionPsychotropic MedicationAnimal Models	2012	60
Changes in brain somatostatin in memory-deficient rats: comparison with cholinergic markers Naoki Matsuoka, Mayako Yamazaki, Isamu Yamaguchi Neuroscience Cholinergic MarkersNeuropsychologyMemory-deficient RatsBrain FunctionNeurophysiology	1995	54
Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats Mayako Yamazaki, Noriyuki Yamamoto, Junko Yarimizu, Journal of Pharmacological Sciences	2015	39
Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks. Naoki Matsuoka, Noriaki Maeda, Mayako Yamazaki, Journal of Pharmacology and Experimental Therapeutics	1992	38
FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action. Mayako Yamazaki, N. Matsuoka, Noriaki Maeda, Journal of Pharmacology and Experimental Therapeutics	1996	38
ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia Mayako Yamazaki, Katsuya Harada, Noriyuki Yamamoto, European Neuropsychopharmacology Asp5736-induced Cognitive EnhancementPsychopharmacologyPharmacotherapyExperimental PharmacologySocial Sciences	2014	37
The Possible Role of Age-Related Increase in the Plasma Glucagon/Insulin Ratio in the Enhanced Hepatic Gluconeogenesis and Hyperglycemia in Genetically Diabetic (C57BL/KsJ-db/db) Mice Hiroshi Kodama, Masataka Fujita, Mayako Yamazaki, The Japanese Journal of Pharmacology NutritionPlasma Glucagon/insulinInsulin SignalingDb/db MiceObesity	1994	32
FR121196, a potential antidementia drug, ameliorates the impaired memory of rat in the Morris water maze. Mayako Yamazaki, Naoki Matsuoka, Noriaki Maeda, Journal of Pharmacology and Experimental Therapeutics	1995	30
Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability Ayaka Chino, Naoyuki Masuda, Y. Amano, Bioorganic & Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceNovel Benzimidazole DerivativesBiochemistryPhosphodiesterase 10A	2014	27
Fragment-Based Discovery of Pyrimido[1,2-<i>b</i>]indazole PDE10A Inhibitors Ayaka Chino, Ryushi Seo, Y. Amano, Chemical and Pharmaceutical Bulletin	2018	24

Page 1